Ellagitannins have been gaining attention as potential anticancer molecules. However, the low bioavailability of ellagitannins and their extensive metabolization in the gastrointestinal tract into ellagic acid and urolithins suggest that the health benefits of consuming ellagitannins rely on the direct effects of their metabolites. Recently, chemopreventive and chemotherapeutic activities were ascribed to urolithins. Nonetheless, there is still a need to screen and evaluate the selectivity of these molecules and to elucidate their cellular mechanisms of action. Therefore, this work focused on the antiproliferative effects of urolithins A, B and C and ellagic acid on different human tumor cell lines. The evaluation of cell viability and the determination of the half-maximal inhibitory concentrations indicated that the sensitivity to the studied urolithins varied markedly between the different cell lines, with the bladder cancer cells (UMUC3) being the most susceptible. In UMUC3 cells, urolithin A was the most active molecule, promoting cell cycle arrest at the G2/M checkpoint, increasing apoptotic cell death and inhibiting PI3K/Akt and MAPK signaling. Overall, the present study emphasizes the chemopreventive/chemotherapeutic potential of urolithins, highlighting the stronger effects of urolithin A and its potential to target transitional bladder cancer cells.
This is a preview of subscription content, log in to check access.
We acknowledge Professor Conceição Pedroso Lima and Doctor Eugénia Carvalho (Center for Neurosciences and Cell Biology, University of Coimbra) for kindly supplying the HepG2 and BJ cell lines, respectively. We also thank the assistance of the CNC Flow Cytometry Core Facility, where the flow cytometry experiments were performed.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The study was supported by the European Regional Development Fund (ERDF) through the Centro 2020 Regional Operational Programme: (project CENTRO-01-0145-FEDER-000012-HealthyAging2020), the COMPETE 2020 Operational Programme for Competitiveness and Internationalisation, the Portuguese national funds via the FCT (Fundação para a Ciência e a Tecnologia, I.P.; project POCI-01-0145-FEDER-007440) and a Ph.D. fellowship (SFRH/BD/72918/2010).
This article does not contain any data from studies involving human participants or animals.
Ascacio-Valdes JA, Buenrostro-Figueroa JJ, Aguilera-Carbo A et al (2011) Ellagitannins: biosynthesis, biodegradation and biological properties. J Med Plants Res 5:4696–4703Google Scholar
Liberal J, Costa G, Carmo A et al (2015) Chemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves. Arab J Chem. doi:10.1016/j.arabjc.2015.11.014
Whitley AC, Sweet DH, Walle T (2006) Site-specific accumulation of the cancer preventive dietary polyphenol ellagic acid in epithelial cells of the aerodigestive tract. J Pharm Pharmacol 58:1201–1209. doi:10.1211/jpp.58.9.0006CrossRefPubMedGoogle Scholar
Espín JC, González-Barrio R, Cerdá B et al (2007) Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 55:10476–10485. doi:10.1021/jf0723864CrossRefPubMedGoogle Scholar
Cerdá B, Espín JC, Parra S et al (2004) The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 43:205–220. doi:10.1007/s00394-004-0461-7CrossRefPubMedGoogle Scholar
Selma MV, Beltrán D, García-Villalba R et al (2014) Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct 5:1779–1784. doi:10.1039/c4fo00092gCrossRefPubMedGoogle Scholar
Larrosa M, González-Sarrías A, Yáñez-Gascón MJ et al (2010) Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-a in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 21:717–725. doi:10.1016/j.jnutbio.2009.04.012CrossRefPubMedGoogle Scholar
González-Sarrías A, Giménez-Bastida JA, García-Conesa MT et al (2010) Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 54:311–322. doi:10.1002/mnfr.200900152CrossRefPubMedGoogle Scholar
Nuñez-Sánchez MA, García-Villalba R, Monedero-Saiz T et al (2014) Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol Nutr Food Res 58:1199–1211. doi:10.1002/mnfr.201300931CrossRefPubMedGoogle Scholar
González-Barrio R, Borges G, Mullen W, Crozier A (2010) Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. J Agric Food Chem 58:3933–3939. doi:10.1021/jf100315dCrossRefPubMedGoogle Scholar
González-Barrio R, Truchado P, Ito H et al (2011) UV and MS identification of Urolithins and Nasutins, the bioavailable metabolites of ellagitannins and ellagic acid in different mammals. J Agric Food Chem 59:1152–1162. doi:10.1021/jf103894mCrossRefPubMedGoogle Scholar
Seeram NP, Henning SM, Zhang Y et al (2006) Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 136:2481–2485PubMedGoogle Scholar
Larrosa M, González-Sarrías A, García-Conesa MT et al (2006) Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 54:1611–1620. doi:10.1021/jf0527403CrossRefPubMedGoogle Scholar
Vicinanza R, Zhang Y, Henning SM, Heber D (2013) Pomegranate juice metabolites, Ellagic acid and Urolithin a, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. Evid Based Complement Alternat Med 2013:247504. doi:10.1155/2013/247504CrossRefPubMedPubMedCentralGoogle Scholar
Kasimsetty SG, Bialonska D, Reddy MK et al (2009) Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. J Agric Food Chem 57:10636–10644. doi:10.1021/jf902716rCrossRefPubMedGoogle Scholar
Seeram NP, Aronson WJ, Zhang Y et al (2007) Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55:7732–7737. doi:10.1021/jf071303gCrossRefPubMedGoogle Scholar
Kallio T, Kallio J, Jaakkola M et al (2013) Urolithins display both antioxidant and pro-oxidant activities depending on assay system and conditions. J Agric Food Chem 61:10720–10729. doi:10.1021/jf403208dCrossRefPubMedGoogle Scholar
Adams LS, Zhang Y, Seeram NP et al (2010) Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila) 3:108–113. doi:10.1158/1940-6207.CAPR-08-0225CrossRefGoogle Scholar
Doherty SC, McKeown SR, McKelvey-Martin V et al (2003) Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst 95:1859–1868CrossRefPubMedGoogle Scholar
Chang F, Lee JT, Navolanic PM et al (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603. doi:10.1038/sj.leu.2402824CrossRefPubMedGoogle Scholar
Wu X, Obata T, Khan Q et al (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93:143–150CrossRefPubMedGoogle Scholar
Knowles MA, Hurst CD (2014) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25–41. doi:10.1038/nrc3817CrossRefGoogle Scholar
González-Sarrías A, Espín J-C, Tomás-Barberán FA, García-Conesa M-T (2009) Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. Mol Nutr Food Res 53:686–698. doi:10.1002/mnfr.200800150CrossRefPubMedGoogle Scholar
González-Sarrías A, Tomé-Carneiro J, Bellesia A et al (2015) The ellagic acid-derived gut microbiota metabolite, urolithin a, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct 6:1460–1469. doi:10.1039/c5fo00120jCrossRefPubMedGoogle Scholar
Sánchez-González C, Ciudad CJ, Izquierdo-Pulido M, Noé V (2015) Urolithin a causes p21 up-regulation in prostate cancer cells. Eur J Nutr. doi:10.1007/s00394-015-0924-z
Truchado P, Larrosa M, García-Conesa MT et al (2012) Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. J Agric Food Chem 60:5749–5754. doi:10.1021/jf203641rCrossRefPubMedGoogle Scholar